California Senator Scott Wiener’s (D-San Francisco) legislation, Senate Bill 519, which decriminalizes the possession and personal use of certain psychedelic drugs including so-called magic mushrooms, passed Assembly Public Safety. The vote was 5-3. Weiner stated that research from top medical universities shows that these substances can have significant benefits, particularly for treating mental health and substance use disorders. Weiner added that decriminalizing their personal possession and use is part of the larger movement to end the racist War on Drugs and its failed and destructive policies.
SB 519 does not decriminalize the sale of psychedelics including magic mushrooms or providing any kind of psychedelics to anyone under the age of 21.
The following substances are included in SB 519: psilocybin, psilocyn, methylenedioxymethamphetamine (“MDMA”), Lysergic acid diethylamide (“LSD”), Dimethyltryptamine (“DMT”), mescaline (excluding peyote), and ibogaine. In addition to that, SB 519 establishes a task force charged with producing recommendations to the Legislature regarding which regulatory system it recommends California adopt for personal use of these specified substances in the future.
Weiner's office stated that this legislation follows similar successful efforts to decriminalize these substances in Washington, D.C., Oakland, and Santa Cruz, as well as the successful 2020 Oregon ballot measures that decriminalized personal use of all scheduled substances, and authorized the creation of a state-licensed, psilocybin services program over the next two years.
"An increasing array of scientific studies shows that psychedelics have great promise in the treatment of mental health and substance use disorders," Weiner's office stated. "Recent clinical trials studying MDMA as a treatment for PTSD led the FDA to distinguish MDMA-assisted therapy as a “Breakthrough Therapy”: two-thirds of study participants no longer qualified as having PTSD after experiencing MDMA-assisted therapy. In a 2018 clinical trial, MDMA treatment showed promise in treating chronic Post-Traumatic Stress Disorder (PTSD) in military veterans, firefighters, and police officers. In a 2020 study, MDMA used in combination with therapy showed the potential to reduce anxiety in patients facing life-threatening illnesses. In both 2018 and 2019, the FDA issued Breakthrough Therapy distinction to psilocybin (the active ingredient in “magic mushrooms”)."
"As we emerge from COVID-19, it’s clear that our mental health and addiction crises are worsening," Weiner said. "With so many people dealing with unemployment and financial distress, community and social isolation, and loss of friends and family to the virus — anxiety, depression, overdose and suicide rates are up across the country. And with prisons and jails serving as COVID-19 hotspots, it’s critical that we look to alternatives to criminalizing and incarcerating people who are using psychedelics to heal.
"SB 519 is co-sponsored by combat veteran service organizations Heroic Hearts Project and Veterans Exploring Treatment Solutions (VETS). Heroic Hearts is an organization that connects veterans to psychedelic therapy for treating complex trauma. In the past few years, Heroic Hearts has become an international voice for veterans demanding effective mental health treatment options. VETS is an organization working to end the veteran suicide epidemic. VETS provides resources, research, and advocacy for U.S. military veterans seeking psychedelic-assisted therapies for traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), addiction, and other mental health conditions."
This is original content from NewsBreak’s Creator Program. Join today to publish and share your own content.